Vim-Deep Brain Stimulation for Familial Tremor

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Familial Tremor
Vim-Deep Brain Stimulation - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will use subject-specific computational models to guide clinicians in choosing stimulation settings for deep brain stimulation targeting the Vim thalamus, an FDA-approved neuromodulation therapy for treating postural and action tremor in individuals with essential tremor.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: 24-months

24-months
Objective Measures of Tremor
Quality of Life Questionnaire: QUEST
Quality of Life Questionnaire: TETRAS
Therapeutic Windows

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Deep Brain Stimulation
1 of 1

Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: Vim-Deep Brain Stimulation · No Placebo Group · N/A

Deep Brain Stimulation
Device
Experimental Group · 1 Intervention: Vim-Deep Brain Stimulation · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24-months

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,243 Previous Clinical Trials
1,481,478 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a diagnosis of ET.
You have a medication-refractory tremor.
A pre-operative MRI scan is performed under Dr

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: November 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.